Studies have shown that women suffering from depression during pregnancy can put the child at risk of developing malformations.  As such, selective serotonin reuptake inhibitors (SSRIs) are most commonly prescribed to the mother to avoid such complications.  Unfortunately, using these drugs during pregnancy may also put the child at risk of malformations.  To date

The objective of a study titled “Neonatal Abstinence Syndrome After in Utero Exposure to Selective Serotonin Reuptake inhibitors in Term Infants”, written by researchers from the Neonatal Intensive Care Unit at Schneider Children’s Medical Center of Israel, led by R. Levinson-Castiel was to determine the prevalence and clinical characteristics of neonatal abstinence syndrome

A study conducted by the Department of Psychological Medicine, King Edward Memorial Hospital for Women, Subiaco, Australia, titled “Placental Transfer of SSRI and SNRI Antidepressants and Effects On The Neonate”, investigated placental transfer and neurobehavioural effects in neonates exposed to venlafaxine (Effexor), sertraline (Zoloft), paroxetine (Paxil), fluvoxamine, fluoxetine (Prozac), escitalopram, and citalopram (Celexa).  

The objective of a study published by researchers from the OMNI Research Group within the Department of Obstetrics and Gynaecology at The University of Ottawa, in Ottawa ON, titled “The Use of Selective Serotonin Reuptake Inhibitors in Pregnancy”, was to update literature on the safety of using selective serotonin reuptake inhibitors during pregnancy.

Studies have shown that 3 percent of pregnant women are treated with antidepressants during gestation.  This percentage is found to slightly increase after delivery of the baby, from 5-7 percent.  Fluoxetine, paroxetine, sertraline, citalopram, and venlafaxine (VENF) are all serotonin reuptake inhibitors or serotonin and noradrenaline reuptake inhibitors that are most commonly prescribed during pregnancy.  

A 2007 review published in Pharmacotherapy analyzed the effects of several common antidepressant medications during pregnancy and concluded that “Third-trimester exposure to newer antidepressants, including SSRIs and serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine), has been associated with a poor neonatal adaptation syndrome. In addition, SSRI use may be associated with an increased risk of persistent pulmonary

Venlafaxine (Effexor) has become a popular antidepressant medication, used to treat major depression and anxiety disorders in adults.  The antidepressant has been widely used, seen as a highly effective medication for patients across a broad demographic.  A current study conducted by Kara Polen, et. al. concerned itself with the lack of research done on Venlafaxine’s